Back to Results
First PageMeta Content
Organofluorides / Amines / Organochlorides / Alkynes / Erlotinib / Gefitinib / Tyrosine-kinase inhibitor / Afatinib / Epidermal growth factor receptor / Chemistry / Organic chemistry / Quinazolines


Abstract # 1048 Phase I study of HM61713, a novel epidermal growth factor receptor (EGFR) mutant selective inhibitor, in non-small cell lung cancer (NSCLC) patients having an activating EGFR mutation but failed to prior
Add to Reading List

Document Date: 2014-03-27 02:03:41

Open Document

File Size: 1,38 MB

Share Result on Facebook

City

Seoul / /

Company

Hanmi Pharmaceutical / AEs / 4Hanmi Pharmaceutical Co. Ltd. / Samsung / /

Country

Korea / /

Facility

University of Ulsan College / Samsung Medical Center / Seoul National University Bundang Hospital / Severance Hospital / Seoul National University Hospital / Mary’s Hospital / Asan Medical Center / /

IndustryTerm

real time / /

MedicalCondition

Tumor / Abdominal pain / Disease / Headache / NSCLC / Dermatitis / S et al. Nature Rev Cancer / progressive disease / Nausea / skin rash / Stomatitis / Alopecia / patients Vomiting / EGFR mutant lung cancer / Fatigue / Urticaria / non-small cell lung cancer / Clinical activity Tumor / Diarrhea / inflammation / Pruritus / Rash / Rev Cancer / /

MedicalTreatment

chemotherapy / Chemotherapies / /

MusicGroup

Nausea / /

Organization

Ulsan College of Medicine / Severance Hospital / Seoul National University Bundang Hospital / Seoul St. Mary’s Hospital / Seoul National University Hospital / Asan Medical Center / /

Person

Jae Cheol / Pao W et al. Nat / Tae Min / /

Position

investigator / /

Technology

Pharmacokinetics / chemotherapy / /

SocialTag